|Bid||7,005.00 x 0|
|Ask||7,005.00 x 0|
|Day's range||6,918.00 - 7,027.00|
|52-week range||5,312.00 - 7,583.00|
|Beta (3Y monthly)||1.05|
|PE ratio (TTM)||40.91|
|Earnings date||24 Oct 2019|
|Forward dividend & yield||2.19 (3.17%)|
|1y target est||78.83|
Britain's blue-chip index ended flat on Tuesday as losses in oil major BP, triggered by a report that Saudi Arabia's output could be back up quicker than expected, were countered by gains in so-called defensive sectors. The FTSE 100 was marginally down at 0.01%. The FTSE 250 fell 0.1%, dragged lower by a collapse in the shares of fertiliser maker Sirius Minerals after the company cancelled the bond tender at the heart of a crucial project in northern England.
AstraZeneca today announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction or preserved ejection fraction .
AstraZeneca (LON:AZN) is a well-known pharmaceuticals giant that focuses on three main therapy areas: Oncology, Cardiovascular amp;amp; Metabolic Disease (CVM8230;
The U.S. Food and Drug Administration (FDA) granted the status for development of the drug to reduce the risk of deadly heart attacks and disease progression in adults with the HFrEF and HFpEF subtypes of heart failure, the British drugmaker said on Monday. Farxiga, already approved as a treatment for type-2 diabetes, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.
I think these two FTSE 100 (INDEXFTSE:UKX) companies could offer resilient growth to boost your overall returns.
London's FTSE 100 overcame early losses to close higher on Tuesday as hopes of imminent interest rate cuts from major central banks buoyed sentiment, while JD Sports jumped to an all-time high on upbeat results. The blue-chip index added 0.4%, with JD Sports gaining 8.8% after its gym clothing and premium-branded fashion helped it post higher profit and offset UK retail sector gloom. The FTSE 250 rose 0.3%, helped in part by a nearly 13% surge in Cairn Energy as strong half-year results led to a production target upgrade.
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone
London's FTSE 100 fell on Monday as the pound ploughed ahead after unexpectedly robust economic data and as no-deal Brexit worries tempered, leaving internationally-focussed stocks in the dumps. The blue-chip index lost 0.6%, shedding earlier gains and lagging its European peers, due to steep falls in pharmaceutical shares AstraZeneca, GlaxoSmithKline , and consumer goods giant Unilever. The FTSE 250 index dipped 0.1%, though losses were limited thanks to a 10.4% surge in Intu Properties after the Times reported that private equity firm Orion Capital Managers was looking to buy the shopping centre operator.
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs. Patients in a reference group on chemotherapy only lived a median 10.3 months in the so-called Caspian trial, it said. "There is a wide recognition that in small cell lung cancer there is very much a need for new therapies," said Dave Fredrickson, head of the company's oncology business.
Canada's main pharmaceutical industry lobby group, along with 16 of its member companies, filed a lawsuit on Friday to block new regulations meant to lower patented drug prices, the second legal challenge to a new regime that could eventually reduce prices in the United States as well. Canada published the final regulations in August, despite heavy lobbying from drug companies, which stand to lose revenue as prices drop. The federal government estimates the new rules will save Canadian patients, employers and insurers, including governments, C$13.2 billion ($10 billion) over a decade.
London's FTSE 100 slipped on Thursday as a surge in sterling pushed exporter stocks lower, missing out on a global rally led by growing hopes of a resolution to the U.S.-China trade dispute. The FTSE 100 slid 0.6%, with multinationals including spirits company Diageo, pharma giants AstraZeneca and GlaxoSmithKline slipping about 3% as a strong pound meant the value of their U.S. earnings was lower. Stocks trading without dividend entitlement on the day such as BHP, Glencore and Micro Focus fell between 1.2%-3%, weighing heavily on the blue-chip index.
China approved Tagrisso as a first-line treatment for adults with non-small cell lung cancer patients whose tumours have certain genetic mutations, AstraZeneca said. Last month, the British drugmaker said a late-stage study showed Tagrisso had significantly helped patients with epidermal growth factor receptor-mutated metastatic non-small cell lung cancer live longer.
AstraZeneca Plc said on Wednesday it had received marketing authorisation from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer. China approved Tagrisso as a first-line treatment for adults with non-small cell lung cancer patients whose tumours have certain genetic mutations, AstraZeneca said.
Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch
Recent cardiovascular trial results are great news for shareholders of AstraZeneca plc (LON: AZN) but would they make me buy?
European stocks closed higher in thin trading on Monday, with investors favouring defensive sectors as the United States and China imposed more tariffs, while a slide in the pound helped Britain's FTSE 100 outperform. After a tumultuous month, equity investors largely shrugged off the latest escalation in the trade spat as Washington began imposing 15% tariffs on a variety of Chinese goods on Sunday and Beijing reciprocated with new duties on U.S. crude oil. London shares jumped 1%, outpacing their European peers, as the internationally focused stocks got a boost from a a slump in sterling on fresh Brexit worries.
London's FTSE 100 surged 1% on Monday, shrugging off news of the latest U.S.-China trade tariffs, as exporter stocks firmed following a slide in sterling on the prospect of an election against the backdrop of Brexit. The main index hit its highest in nearly a month, partly boosted by AstraZeneca, which rose 3% to an all-time high after separate trials showed its drugs helped patients with cardiovascular conditions. The mid-cap FTSE 250 rose 0.5%, though trading volumes on both UK indexes were thin due to a U.S. market holiday.
London's main index jumped on Thursday as China's fresh comments on possibly resolving the long-drawn trade spat with the United States lifted investor spirits, while exporter stocks gained as sterling fell after the suspension of parliament raised concerns of a no-deal Brexit. The main index added 1%, as internationally exposed firms such as HSBC and AstraZeneca rose and offset a 32% plunge in Micro Focus after the IT group warned on its full-year revenue. The FTSE 250 midcap index ended up 0.4%, with gains capped due to a more than 50% drop in consumer credit provider Amigo Holdings following an annual forecast cut.
AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage study, an encouraging sign after it failed to meet its main target in the final stage of another trial last year. The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final stage of one of the two clinical trials under the TULIP program last year https://in.reuters.com/article/us-astrazeneca-anifrolumab/astrazeneca-lupus-drug-fails-to-meet-main-goal-in-study-idINKCN1LG0MM.
The British drugmaker said anifrolumab under the TULIP 2 programme helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final stage of one of the two clinical trials under the TULIP program last year https://in.reuters.com/article/us-astrazeneca-anifrolumab/astrazeneca-lupus-drug-fails-to-meet-main-goal-in-study-idINKCN1LG0MM. "These are important results and we will now review the full data set and explore pathways to bring this potential new treatment to patients," said Mene Pangalos, executive vice president BioPharmaceuticals R&D, adding that only one new treatment has been approved for the disease in the last 60 years.
Sep.09 -- AstraZeneca PLC is betting on sales of its new drug to outweigh that of off-patient ones in China over the next five years amid Chinese regulator's expedited approval of new therapies to meet unmet medical demands. Leon Wang, it's executive vice president overseeing international markets, spoke exclusively to Selina Wang on "Bloomberg Daybreak: Asia.